RxDoctor Payments Data

Rohit Goyal, MD

Critical Care Medicine · Fredericksburg, VANPI 1881879724

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $62,351 of the $95,201 with a category attached, or 65.5%. Pulmonx Corporation accounts for 66.7% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2023 at $55,332 and has fallen 83.0% since, to $9,432 in 2025. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,201in general payments, 2019–2025

Across 694 payments — averaging $137.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$63K
  • Intuitive Surgical$8K
  • United Therapeutics Corporation$7K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • GSK$2K
  • plus $11K from 47 others

What the payments were for

  • Consulting fees$62,35165%
  • Travel & lodging$11,31412%
  • Food & beverage$16,44017%
  • Education$5,0835%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,201 in reported general payments places this provider in the 95th percentile of 174 critical care medicine providers in Virginia.

See all critical care medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$1,152,513
Medicare patients
1,733
Services billed
18,716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate17$223,018
Prolastin CAlpha-1-Proteinase Inhibitor22$178,588
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$177,493
GlassiaAlpha-1-Proteinase Inhibitor12$104,008
Breztri AerosphereBudesonide/Glycopyr/Formoterol66$60,407
Breo ElliptaFluticasone/Vilanterol68$41,365
Spiriva RespimatTiotropium Bromide27$26,816
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$25,130
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$15,538
SymbicortBudesonide/Formoterol Fumarate27$10,676
Advair HfaFluticasone Propion/Salmeterol13$9,368
Albuterol Sulfate HfaAlbuterol Sulfate198$5,707
Wixela InhubFluticasone Propion/Salmeterol26$4,625
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$3,894
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate20$2,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,053$265,37368 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,630$243,988293 claims
Grifols USA, LLCProlastin C$223$178,58822 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$783$104,00812 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,051$71,08393 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 critical care medicine providers in Virginia.

Other critical care medicine in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →